Association of Circulating Tumor DNA Testing Before Tissue Diagnosis With Time to Treatment Among Patients With Suspected Advanced Lung Cancer
JAMA Network Open · 25.07.2023 · 6 (7) · e2325332
DOI: 10.1001/jamanetworkopen.2023.25332 ↗Kurz gefasst
Klinische Studie in der Zeitschrift JAMA Network Open, online erschienen am 25.07.2023. Verfasst von Miguel García-Pardo und 28 weiteren Autor:innen. Beteiligte Einrichtung: Division of Medical Oncology and Hematology, Princess Margaret Cancer Centre, University Health Network, Toronto, Ontario, Canada. Hauptthemen laut MEDLINE: Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Circulating Tumor DNA. Die Arbeit wurde bisher 61-mal zitiert (Crossref) und nennt 36 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.
Abstract (Originalsprache)
Importance Liquid biopsy has emerged as a complement to tumor tissue profiling for advanced non–small cell lung cancer (NSCLC). The optimal way to integrate liquid biopsy into the diagnostic algorithm for patients with newly diagnosed advanced NSCLC remains unclear.
Objective
To evaluate the use of circulating tumor DNA (ctDNA) genotyping before tissue diagnosis among patients with suspected advanced NSCLC and its association with time to treatment. Design, Setting, and Participants This single-group nonrandomized clinical trial was conducted among 150 patients at the Princess Margaret Cancer Centre–University Health Network (Toronto, Ontario, Canada) between July 1, 2021, and November 30, 2022. Patients referred for investigation and diagnosis of lung cancer were eligible if they had radiologic evidence of advanced lung cancer prior to a tissue diagnosis.
Interventions
Patients underwent plasma ctDNA testing with a next-generation sequencing (NGS) assay before lung cancer diagnosis. Diagnostic biopsy and tissue NGS were performed per standard of care. Main Outcome and Measures The primary end point was time from referral to treatment initiation among patients with advanced nonsquamous NSCLC using ctDNA testing before diagnosis (ACCELERATE [Accelerating Lung Cancer Diagnosis Through Liquid Biopsy] cohort). This cohort was compared with a reference cohort using standard tissue genotyping after tissue diagnosis.
Results
Of the 150 patients (median age at diagnosis, 68 years [range, 33-91 years]; 80 men [53%]) enrolled, 90 (60%) had advanced nonsquamous NSCLC. The median time to treatment was 39 days (IQR, 27-52 days) for the ACCELERATE cohort vs 62 days (IQR, 44-82 days) for the reference cohort ( P < .001). Among the ACCELERATE cohort, the median turnaround time from sample collection to genotyping results was 7 days (IQR, 6-9 days) for plasma and 23 days (IQR, 18-28 days) for tissue NGS ( P < .001). Of the 90 patients with advanced nonsquamous NSCLC, 21 (23%) started targeted therapy before tissue NGS results were available, and 11 (12%) had actionable alterations identified only through plasma testing. Conclusions and Relevance This nonrandomized clinical trial found that the use of plasma ctDNA genotyping before tissue diagnosis among patients with suspected advanced NSCLC was associated with accelerated time to treatment compared with a reference cohort undergoing standard tissue testing. Trial Registration ClinicalTrials.gov Identifier: NCT04863924
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Division of Medical Oncology and Hematology, Princess Margaret Cancer Centre, University Health Network, Toronto, Ontario, Canada.
- Department of Medicine, University of Barcelona, Barcelona, Spain.
- Department of Medical Oncology, Hospital Universitario Ramón y Cajal, Madrid, Spain.
- Division of Thoracic Surgery, University Health Network, Toronto, Ontario, Canada.
- Department of Biostatistics, Princess Margaret Cancer Centre, University Health Network, Toronto, Ontario, Canada.
- Department of Medical Oncology, Inselspital, Bern University Hospital, University of Bern, Bern, Switzerland.
Zitieren
APA
García-Pardo, M., Czarnecka-Kujawa, K., Law, J. H., Salvarrey, A. M., Fernandes, R., Fan, Z. J., Waddell, T. K., Yasufuku, K., Liu, G., Donahoe, L. L., Pierre, A., Le, L. W., Gunasegaran, T., Ghumman, N., Shepherd, F. A., Bradbury, P. A., Sacher, A. G., Schmid, S., Corke, L., …, & Leighl, N. B. (2023). Association of Circulating Tumor DNA Testing Before Tissue Diagnosis With Time to Treatment Among Patients With Suspected Advanced Lung Cancer. JAMA Network Open, 6(7), e2325332. https://doi.org/10.1001/jamanetworkopen.2023.25332
Vancouver
García-Pardo M, Czarnecka-Kujawa K, Law JH, Salvarrey AM, Fernandes R, Fan ZJ, et al. Association of Circulating Tumor DNA Testing Before Tissue Diagnosis With Time to Treatment Among Patients With Suspected Advanced Lung Cancer. JAMA Network Open. 2023;6(7):e2325332. doi:10.1001/jamanetworkopen.2023.25332
BibTeX
@article{GarcaPardo2023,
author = {García-Pardo, Miguel and Czarnecka-Kujawa, Kasia and Law, Jennifer H and Salvarrey, Alexandra M and Fernandes, Roxanne and Fan, Zhen J and Waddell, Thomas K and Yasufuku, Kazuhiro and Liu, Geoffrey and Donahoe, Laura L and Pierre, Andrew and Le, Lisa W and Gunasegaran, Tharsiga and Ghumman, Noor and Shepherd, Frances A and Bradbury, Penelope A and Sacher, Adrian G and Schmid, Sabine and Corke, Lucy and Feng, Jamie and Stockley, Tracy and Pal, Prodipto and Rogalla, Patrik and Pipinikas, Christodoulos and Howarth, Karen and Ambasager, Bana and Mezquita, Laura and Tsao, Ming S and Leighl, Natasha B},
title = {Association of Circulating Tumor DNA Testing Before Tissue Diagnosis With Time to Treatment Among Patients With Suspected Advanced Lung Cancer},
journal = {JAMA Network Open},
year = {2023},
volume = {6},
number = {7},
pages = {e2325332},
doi = {10.1001/jamanetworkopen.2023.25332}
}
EUVIMED